ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 191 filers reported holding ASCENDIS PHARMA A/S in Q4 2022. The put-call ratio across all filers is 0.20 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $1 | -99.9% | 24 | +50.0% | 0.00% | – |
| Q3 2022 | $1,000 | -90.9% | 16 | -87.5% | 0.00% | – |
| Q2 2022 | $11,000 | +1000.0% | 128 | +1180.0% | 0.00% | – |
| Q1 2022 | $1,000 | -66.7% | 10 | -65.5% | 0.00% | – |
| Q4 2021 | $3,000 | -50.0% | 29 | -42.0% | 0.00% | – |
| Q2 2021 | $6,000 | 0.0% | 50 | 0.0% | 0.00% | – |
| Q1 2021 | $6,000 | -45.5% | 50 | -50.0% | 0.00% | – |
| Q1 2020 | $11,000 | -21.4% | 100 | 0.0% | 0.00% | – |
| Q4 2019 | $14,000 | +40.0% | 100 | 0.0% | 0.00% | – |
| Q3 2019 | $10,000 | -16.7% | 100 | 0.0% | 0.00% | – |
| Q2 2019 | $12,000 | 0.0% | 100 | 0.0% | 0.00% | – |
| Q1 2019 | $12,000 | – | 100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management III, LLC | 133,691 | $13,805,000 | 36.44% |
| RA Capital Management | 7,567,900 | $781,462,000 | 16.67% |
| Q Global Advisors, LLC | 145,209 | $16,699,000 | 11.49% |
| BERYLSON CAPITAL PARTNERS, LLC | 51,000 | $5,266,000 | 8.70% |
| Spyglass Capital Management LLC | 949,915 | $98,088,000 | 6.94% |
| Paradigm Biocapital Advisors LP | 497,347 | $51,356,000 | 6.85% |
| Avoro Capital Advisors LLC | 2,850,000 | $294,291,000 | 5.44% |
| Deep Track Capital, LP | 1,000,000 | $103,260,000 | 4.73% |
| Finepoint Capital LP | 123,400 | $12,742,000 | 4.19% |
| Deep Track Capital, LP | 800,000 | $82,608,000 | 3.78% |